What does the hiring of a well known business dealmaker imply for the way forward for BioMarin Prescribed drugs? Can Eli Lilly’s blockbuster weight problems drugs decrease the danger of diabetes? And can Recursion Pharma, the AI drug developer, reside as much as all of the hype?
We talk about all that and extra on this week’s episode of “The Readout LOUD.”
It’s a guest-free episode this week, giving Allison, Adam and Elaine ample time to speak concerning the administration shakeup at BioMarin, together with the announcement that James Sabry, the previous Roche dealmaker, was becoming a member of the corporate as its new chief enterprise officer. We will’t appear to go per week with out speaking about GLP-1 medicines, so in true type, Elaine walks us by new research findings that confirmed Lilly’s Zepbound vastly decreased the danger of diabetes. We additionally talk about a separate research that doubtlessly hyperlinks GLP-1 medication to a better price of suicidal ideas.
Lastly, Adam and Elaine interrogate Allison about her deeply reported company profile of AI drug developer Recursion. Is all of the hype actual?
For extra on Lilly’s Zepbound diabetes research, go right here. For a writeup of the suicide ideation research, look right here. And Allison’s sweeping profile of Recursion might be discovered right here.
Make certain to enroll in “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
